AI Summary
Exagen expects $66M to $67M total revenue for 2025. Revenue growth projected at 19% to 20% year-over-year. AVISE CTD test volume increased to 136,000 to 137,000 units. Year-end cash balance rose by $10 million to $32 million.
Sentiment Rationale
Exagen's revenue growth and cash position reflect solid performance, improving investor sentiment.
Trading Thesis
The boost from preliminary results is likely to affect the stock price in coming weeks.
Market-Moving
- Exagen expects $66M to $67M total revenue for 2025.
- Revenue growth projected at 19% to 20% year-over-year.
- AVISE CTD test volume increased to 136,000 to 137,000 units.
Key Facts
- Exagen expects $66M to $67M total revenue for 2025.
- Revenue growth projected at 19% to 20% year-over-year.
- AVISE CTD test volume increased to 136,000 to 137,000 units.
- Year-end cash balance rose by $10 million to $32 million.
Companies Mentioned
- MDXG (MDXG)
- NVTA (NVTA)
- ICHR (ICHR)
Earnings
The preliminary results indicate strong operational success, suggesting potential for stock price growth.